retatrutide clinical trials latest ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide, Eli Lilly's new experimental

BETA TRUTIDE is a cutting-edge, investigational triple hormone receptor agonist developed to address obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH)

If Im in for a regular checkup and I mention I dont really like the way this is sitting, theyve got advice to give me

Ive had patients report that if they take it too soon, they develop GI side effects like nausea, says Jennifer Brown, MD, obesity medicine physician and expert at My Obesity Team

ALT and AST Alanine aminotransferase and aspartate aminotransferase, liver enzymes measured in blood tests to assess liver health

David Ricks, Chair and Chief Executive Officer of Eli Lilly, noted that fewer than one in ten people who could benefit from a GLP-1 therapy are currently taking one, citing access barriers, stigma, and the complexity of existing treatment options

Wegovy (semaglutide) Summary of Product Characteristics